Last reviewed · How we verify
Allogenic NK cells infusion
At a glance
| Generic name | Allogenic NK cells infusion |
|---|---|
| Also known as | cellular therapy |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (PHASE1)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (PHASE2)
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (PHASE1, PHASE2)
- CIML NK Cells With Venetoclax for AML (PHASE1)
- Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma (PHASE1, PHASE2)
- Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites (PHASE1, PHASE2)
- Natural Killer-cell Therapy for Acute Myeloid Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allogenic NK cells infusion CI brief — competitive landscape report
- Allogenic NK cells infusion updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI